NeoGenomics Launches NeoTYPE™ Prognostic Panel for Chronic Lymphocytic Leukemia; Includes First U.S. Clinical Molecular Test for SF3B1 Mutations
03:48 EDT 6 Aug 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
FT. MYERS, Fla., Aug. 6, 2012 /PRNewswire/ -- NeoGenomics, Inc. (NASD OTC BB: NGNM), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched the first molecular assay for clinical use in the United ...
Other Sources for this Article
More From BioPortfolio on "NeoGenomics Launches NeoTYPE™ Prognostic Panel for Chronic Lymphocytic Leukemia; Includes First U.S. Clinical Molecular Test for SF3B1 Mutations"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
